Margaret R. Jorgenson

Author

Also Known As

Jorgenson, M.R., M. Jorgenson, M. R. Jorgenson, Margaret Jorgenson, Margaret R Jorgenson, Margaret R. Jorgenson, Margaret R. Jorgenson

101

Publications

952

Citations

H-Index

Concepts

All Affiliations

UW Health University Hospital University of Wisconsin–Madison Wisconsin Division of Public Health University of Wisconsin Health

About

Margaret R. Jorgenson is an author at UW Health University Hospital specializing in medicine, transplantation, and infection control.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	169
2	Health Sciences	1	1	72
3	Public Health	1	1	15
4	Epidemiology	1	1	15
5	Immunology	1	1	15

Margaret R. Jorgenson

Publications

459

Citations

H-Index

Page 1

	Year	Citations
Fosfomycin Synergy <i>In Vitro</i> with Amoxicillin, Daptomycin, and Linezolid against Vancomycin-Resistant Enterococcus faecium from Renal Transplant Patients with Infected Urinary Stents Jillian L. Descourouez, Margaret R. Jorgenson, Justine E. Wergin, Antimicrobial Agents and Chemotherapy S. FosfomycinVancomycin-resistant Enterococcus FaeciumAntimicrobial ChemotherapyAntibiotic ResistanceDrug Resistance	2012	72
White paper on antimicrobial stewardship in solid organ transplant recipients Miranda So, Jonathan Hand, Graeme N. Forrest, American Journal of Transplantation TransplantationAntibioticsSolid Organ TransplantationWhite PaperTransplantation Medicine	2021	65
Vancomycin Prophylaxis for Prevention of <i>Clostridium difficile</i> Infection Recurrence in Renal Transplant Patients Lindsey E. Splinter, Luiza Kerstenetzky, Margaret R. Jorgenson, Annals of Pharmacotherapy	2017	32
Risk of opportunistic infection in kidney transplant recipients with cytomegalovirus infection and associated outcomes Margaret R. Jorgenson, Jillian L. Descourouez, Brianna Cardinale, Transplant Infectious Disease	2019	26
Letermovir conversion after valganciclovir treatment in cytomegalovirus high‐risk abdominal solid organ transplant recipients may promote development of cytomegalovirus‐specific cell mediated immunity Margaret R. Jorgenson, Hanna L. Kleiboeker, Neetika Garg, Transplant Infectious Disease	2021	22
Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction Margaret R. Jorgenson, Jillian L. Descourouez, Christopher M. Saddler, Clinical Transplantation	2023	20
The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients Margaret R. Jorgenson, Jillian L. Descourouez, Neetika Garg, Transplant Infectious Disease	2021	19
Pneumocystis jiroveci pneumonia in kidney and simultaneous pancreas kidney transplant recipients in the present era of routine post-transplant prophylaxis: risk factors and outcomes Neetika Garg, Margaret R. Jorgenson, Jillian L. Descourouez, BMC Nephrology	2018	18
Serum Albumin Level Before Kidney Transplant Predicts Post-transplant BK and Possibly Cytomegalovirus Infection Aniruddha Srivastava, Joshua Bodnar, Fauzia Osman, Kidney International Reports	2020	17
Outcomes of Delayed Graft Function in Kidney Transplant Recipients Stratified by Histologic Biopsy Findings Stacey Rolak, Arjang Djamali, Didier A. Mandelbrot, Transplantation Proceedings Transplant RejectionUrologyTransplantationKidney TransplantKidney Transplantation	2021	17

Page 1